Literature DB >> 24311293

Natriuretic peptide receptors and heart failure: to B or not to B blocked?

A J Hobbs1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24311293     DOI： 10.1007/s00210-013-0946-0

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  31 in total

1.  The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. Part 1.

Authors:  C A Veale; V C Alford; D Aharony; D L Banville; R A Bialecki; F J Brown; J R Damewood; C L Dantzman; P D Edwards; R T Jacobs; R C Mauger; M M Murphy; W Palmer; K K Pine; W L Rumsey; L E Garcia-Davenport; A Shaw; G B Steelman; J M Surian; E P Vacek
Journal:  Bioorg Med Chem Lett       Date:  2000-09-04       Impact factor: 2.823

2.  Physiological role of silent receptors of atrial natriuretic factor.

Authors:  T Maack; M Suzuki; F A Almeida; D Nussenzveig; R M Scarborough; G A McEnroe; J A Lewicki
Journal:  Science       Date:  1987-10-30       Impact factor: 47.728

3.  Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice.

Authors:  Yong Wang; Monique C de Waard; Anja Sterner-Kock; Holger Stepan; Heinz-Peter Schultheiss; Dirk J Duncker; Thomas Walther
Journal:  Eur J Heart Fail       Date:  2007-04-03       Impact factor: 15.534

4.  Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B.

Authors:  Thomas H Langenickel; Jens Buttgereit; Ines Pagel-Langenickel; Maren Lindner; Jan Monti; Knut Beuerlein; Nidal Al-Saadi; Ralph Plehm; Elena Popova; Jens Tank; Rainer Dietz; Roland Willenbrock; Michael Bader
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-14       Impact factor: 11.205

5.  In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator.

Authors:  Jeffrey D Edelson; Marie Makhlina; Kevin R Silvester; Shailesh S Vengurlekar; Xiaomei Chen; Jie Zhang; Cynthia J Koziol-White; Philip R Cooper; Trevor J Hallam; Douglas W P Hay; Reynold A Panettieri
Journal:  Pulm Pharmacol Ther       Date:  2012-11-12       Impact factor: 3.410

6.  Discovery of a potent atrial natriuretic peptide antagonist for ANPA receptors in the human neuroblastoma NB-OK-1 cell line.

Authors:  C Delporte; J Winand; P Poloczek; T Von Geldern; J Christophe
Journal:  Eur J Pharmacol       Date:  1992-12-02       Impact factor: 4.432

Review 7.  Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications.

Authors:  Lincoln R Potter; Andrea R Yoder; Darcy R Flora; Laura K Antos; Deborah M Dickey
Journal:  Handb Exp Pharmacol       Date:  2009

8.  Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects.

Authors:  Candace Y W Lee; Horng H Chen; Ondrej Lisy; Suzanne Swan; Courtney Cannon; Hsiao D Lieu; John C Burnett
Journal:  J Clin Pharmacol       Date:  2009-04-24       Impact factor: 3.126

9.  Anantin--a peptide antagonist of the atrial natriuretic factor (ANF). II. Determination of the primary sequence by NMR on the basis of proton assignments.

Authors:  D F Wyss; H W Lahm; M Manneberg; A M Labhardt
Journal:  J Antibiot (Tokyo)       Date:  1991-02       Impact factor: 2.649

10.  Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension.

Authors:  James R Klinger; Sejal Thaker; Jeanne Houtchens; Ioana R Preston; Nicholas S Hill; Harrison W Farber
Journal:  Chest       Date:  2006-02       Impact factor: 9.410
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.